FOR IMMEDIATE RELEASE

 

Contacts:
David Johnston, Chief Financial Officer, AVEO Pharmaceuticals, Inc.
(617) 299-5000

 

Caton Lovett, Pure Communications
(910) 232-7166

AVEO Pharmaceuticals to Present at the
Canaccord Adams 29th Annual Global Growth Conference

 

CAMBRIDGE, Mass., August 4, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Canaccord Adams 29th Annual Global Growth Conference on Tuesday, August 11, 2009 at 3:00 p.m. (EDT) at the InterContinental Hotel in Boston, Mass.

 

About AVEO
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec. The company’s lead product, tivozanib (AV-951), a triple VEGF receptor inhibitor, recently completed Phase 2 clinical development in patients with metastatic renal cell cancer and is expected to enter Phase 3 development in 2009. Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at www.aveopharma.com.